Markets:

Overview

News

Currencies

International

Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

17.98 -0.04 (-0.22%)

Streaming Delayed Price Updated: 1:01 PM EDT, Mar 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Crude Oil Rises; Carnival Shares Drop After Q2 Results ↗

June 26, 2023

U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 80 points on Monday. The Dow traded down 0.02% to 33,719.54 while the NASDAQ fell 0.53% to 13,420.67. The S&P 500, also...

Via Benzinga

MoonLake Immunotherapeutics (NASDAQ: MLTX) Announces Breakthrough Results for Sonelokimab in Phase 2 Trial

June 26, 2023

MoonLake Immunotherapeutics (NASDAQ: MLTX) has made significant strides with the successful outcome of their Phase 2 MIRA trial for sonelokimab,

Via Spotlight Growth

Is the Stock Market Closed on the Fourth of July 2023? ↗

June 26, 2023

Investors are looking for information about the stock market being closed on the Fourth of July and we've got the answers they seek!

Via InvestorPlace

Is the Stock Market Closed on July 3, 2023? ↗

June 26, 2023

Investors are preparing for Independence Day and that has some traders wondering if the stock market is closed on July 3, 2023.

Via InvestorPlace

Insiders Promise Not to Sell AMTD Digital (HKD) Stock Until 2025 ↗

June 26, 2023

AMTD Digital (HKD) stock is on the move Monday after insiders promised not to sell shares on the public market for a few more years.

Via InvestorPlace

The Latest Analyst Ratings for MoonLake ↗

June 15, 2023

Via Benzinga

What 10 Analyst Ratings Have To Say About MoonLake ↗

May 01, 2023

Via Benzinga

Where MoonLake Stands With Analysts ↗

March 20, 2023

Via Benzinga

Wolfspeed, Genesco, PacWest Bancorp And Other Big Stocks Moving Higher On Monday ↗

June 26, 2023

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why Is FibroGen (FGEN) Stock Down 81% Today? ↗

June 26, 2023

FibroGen (FGEN) stock is heading lower on Monday after the company's Phase 3 clinical trial failed to meet its primary endpoint.

Via InvestorPlace

US Stocks Edge Higher; Goldman Sachs Downgrades Tesla To Neutral ↗

June 26, 2023

U.S. stocks traded slightly higher this morning, with the Dow Jones gaining around 25 points on Monday. Following the market opening Monday, the Dow traded up 0.08% to 33,753.64 while the NASDAQ rose...

Via Benzinga

Why Is MoonLake Immunotherapeutics (MLTX) Stock Up 93% Today? ↗

June 26, 2023

MoonLake Immunotherapeutics (MLTX) stock is taking off on Monday after reporting positive results from a Phase 2 clinical trial.

Via InvestorPlace

Why Mutual Fund Darling And Top 1% Stock MoonLake Immunotherapeutics Nearly Doubled ↗

June 26, 2023

The company is treating a painful skin condition and could go up against AbbVie.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 26, 2023

Via Benzinga

Lucid Stock Moved Into the Fast Lane, but This Nasdaq Biotech Was Monday's Big Winner ↗

June 26, 2023

Markets looked poised to start the new week flat.

Via The Motley Fool

Why MoonLake Immunotherapeutics Stock Is Shooting Higher Today ↗

June 26, 2023

MoonLake Immunotherapeutics (NASDAQ: MLTX) released topline results from its Phase 2 MIRA trial evaluating the Nanobody sonelokimab in patients with moderate-to-severe

Via Benzinga

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

June 25, 2023

From MoonLake Immunotherapeutics AG

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗

June 15, 2023

Via Benzinga

10 Short Squeeze Stocks To Watch: Getty Images, Intuitive Machines, Wearable Devices & More ↗

June 12, 2023

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among...

Via Benzinga

10 Short Squeeze Stocks To Watch: AirSculpt, Arrival, Toro, Groupon, Beam Global And More ↗

May 30, 2023

Via Benzinga

10 Short Squeeze Stocks To Watch: Toro Corp, Greenidge Generation, Getty Images And More ↗

May 22, 2023

Via Benzinga

10 Short Squeeze Stocks To Watch: Toro Corp, PaxMedica, Getty Images And More ↗

May 15, 2023

Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High-short interest and high-cost to borrow are among the...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗

May 01, 2023

Via Benzinga

Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 24, 2023

Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment.

Via Benzinga

10 Short Squeeze Stocks To Watch: Getty Images, Guardforce AI And 2 Stocks Moving Up Over 1,000 Positions On The Leaderboard ↗

April 24, 2023

Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the...

Via Benzinga

MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today

April 19, 2023

From MoonLake Immunotherapeutics AG

Via GlobeNewswire

10 Short Squeeze Candidates: Getty Images Tops List, PaxMedica Rejoins Top Five, MicroStrategy Moves Up And More ↗

April 10, 2023

Potential short squeeze plays gained steam in 2021 and continued through 2023 with new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2023 ↗

March 22, 2023

Via Benzinga

Charles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday ↗

March 20, 2023

HC Wainwright & Co. cut the price target for 89bio, Inc. (NASDAQ: ETNB) from $27 to $25. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. 89bio shares fell 5.2% to trade at $11.80 on...

Via Benzinga

Why Bed Bath & Beyond Shares Are Trading Lower By Around 24%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 20, 2023

Gainers

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.